SOTIO is an international biotechnology company leading the efforts of its strategic investor PPF Group to build a diverse pharma company specializing in oncology. SOTIO pursues its goal through in-house research and clinical development, collaboration with external partners, in-licensing deals, investments and acquisitions. The company is developing new therapies focusing on the treatment of cancer and autoimmune diseases.

The most advanced project in the SOTIO development portfolio is based on its proprietary DCVAC platform – an active cellular immunotherapy (ACI) on the basis of dendritic cells. SOTIO is testing safety and efficacy of its DCVAC products in multiple Phase I to Phase III clinical trials in oncology indications.

SOTIO has a geographic presence in Europe, the United States, China and Russia, enabling a global approach to clinical development. The GMP-certified cell therapy manufacturing facility in Prague, one of the largest of its kind in Europe, can manufacture and supply cellular immunotherapy treatment for clinical development in both Europe and the United States. In Beijing, SOTIO manufactures its products in its GMP-compliant cell therapy manufacturing facility built in 2014 for joint research projects and clinical trials conducted by leading hospitals in China.